Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, April 24, 2024 | Back issues
Courthouse News Service Courthouse News Service

Drug Patents

A federal court in California refused to dismiss a False Claims Act suit that claims pharmaceutical companies Allergan and Adamas misled the U.S. Patent Office into issuing “invalid” patents protecting Alzheimer’s drugs Namenda XR and Namzaric, which allegedly allowed the companies to have a monopoly.

SAN FRANCISCO — A federal court in California refused to dismiss a False Claims Act suit that claims pharmaceutical companies Allergan and Adamas misled the U.S. Patent Office into issuing invalid patents protecting Alzheimer’s drugs Namenda XR and Namzaric, which allegedly allowed the companies to have a monopoly. 

Categories / Business, Consumers, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...